Sandbox: manpreet kaur: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 24: | Line 24: | ||
TID or QID | TID or QID | ||
|14 | |14 | ||
|NO(a) | |NO<sup>(a)</sup> | ||
|- | |- | ||
|Levofloxacin triple | |Levofloxacin triple | ||
Line 30: | Line 30: | ||
* PPI(standard dose) | * PPI(standard dose) | ||
* Levofloxacin (500mg) | * Levofloxacin (500mg) | ||
* | * Amoxicillin(1gm) | ||
|BID | |BID | ||
Line 59: | Line 59: | ||
* PPI(standard dose) | * PPI(standard dose) | ||
* Rifabutin(300mg) | * Rifabutin(300mg) | ||
* | * Amoxicillin(1gm) | ||
|BID | |BID | ||
Line 71: | Line 71: | ||
| | | | ||
* PPI(standard to double dose) | * PPI(standard to double dose) | ||
* | * Amoxicillin(1gm TID or 750mg QID) | ||
|TID or QID | |TID or QID | ||
Revision as of 20:16, 27 October 2017
Salvage therapies for Helicobacter pylori infection | ||||
---|---|---|---|---|
Regimen | Drugs(doses) | Dosing frequency | Duration(days) | FDA approval |
Bismuth quadruple |
|
BID
QID QID TID or QID |
14 | NO(a) |
Levofloxacin triple |
|
BID
QD BID |
14 | NO |
Concomitant |
|
BID
BID BID BID or TID |
10-14 | NO |
Rifabutin triple |
|
BID
QD BID |
10 | NO |
High-dose dual |
|
TID or QID
TID or QID |
14 | NO |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Manpreet Kaur, MD [2]
References
- References should be cited for the material that you have put on your page. Type in {{reflist|2}}.This will generate your references in small font, in two columns, with links to the original article and abstract.
- For information on how to add references into your page, click here.